Tozadenant (formerly RO-4494351; SYN-115) is an orally bioavailable, selective adenosine A2A receptor antagonist with potential usefulness in the treatment of Parkinson disease (PD). It inhibits A2A receptor with Ki of 11.5 nM on human A2A and 6 nM on rhesus A2A. It improves motor function in animal models of Parkinson's disease. Adenosine A(2a) receptor antagonists reduce symptom severity in Parkinson disease (PD) and animal models. Rodent studies support the hypothesis that A(2a) antagonists produce this benefit by reducing the inhibitory output of the basal ganglia indirect pathway.

纯度：≥98%

CAS：870070-55-6